Bone Metastasis Management in Lung Cancer

Bone metastases affect a substantial proportion of patients with advanced lung cancer, leading to pain, pathological fractures, spinal cord compression and hypercalcaemia. Early detection through imaging modalities such as bone scintigraphy, PET–CT and MRI, alongside circulating biomarkers of bone turnover, enables timely intervention. Management comprises bone-targeted agents, notably bisphosphonates and RANKL inhibitors, which reduce skeletal-related events and preserve quality of life. Local measures—including palliative radiotherapy and orthopaedic surgery—address pain and structural integrity, while systemic therapies such as targeted agents (for example EGFR-tyrosine kinase inhibitors) and immunotherapies may also modulate bone involvement. Multidisciplinary collaboration is essential to tailor treatment, optimise symptom control and integrate emerging predictive tools—such as nomograms and serological models—into clinical decision-making. Advances in molecular profiling are yielding novel biomarkers and therapeutic targets aimed at improving prognosis and mitigating skeletal complications in this challenging population.

Research from Nature Portfolio

Recent studies offer insight into the natural course and prognostic factors of bone metastases in non-small-cell lung cancer. A large retrospective survey characterised the timing of skeletal involvement, the incidence of skeletal-related events and survival outcomes, and proposed a prognostic score based on age, histology, performance status and concomitant visceral metastases. Another analysis identified histopathological subtype, serum CA-125 and alkaline phosphatase levels as independent risk factors for bone dissemination, underscoring the importance of biochemical screening at diagnosis. Investigations into combined regimens have shown that adding bisphosphonates to EGFR-tyrosine kinase inhibitors in patients with activating EGFR mutations prolongs progression-free survival and trends towards fewer skeletal-related events, establishing mutation status as a key determinant of skeletal management.

Bone Metastasis Management in Lung Cancer publication trend

The graph below shows the total number of articles in bone metastasis management in lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Skeletal-related events (SREs): Clinical complications of bone metastases, including fractures, spinal cord compression and hypercalcaemia.

Bisphosphonates: Agents that inhibit osteoclast-mediated bone resorption to reduce skeletal complications.

RANKL inhibitor: A monoclonal antibody blocking receptor activator of nuclear factor κB ligand to prevent bone turnover.

EGFR-TKIs: Small-molecule inhibitors targeting epidermal growth factor receptor mutations to control tumour growth.

Nomogram: A graphical predictive tool integrating multiple variables to estimate individual risk of clinical outcomes.

References

1. Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition). Journal of the National Cancer Center (2023).
2. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Scientific Reports (2015).
3. Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer. BMC Cancer (2019).
4. The risk factors of bone metastases in patients with lung cancer. Scientific Reports (2017).
5. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Scientific Reports (2017).
6. Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer. BMC Cancer (2020).
7. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. Frontiers in Oncology (2020).